EV Therapeutics

EV Therapeutics is a private, pre-clinical immuno-oncology biotechnology company developing extracellular vesicle-based cancer therapies. The company is focused on off-the-shelf neoantigen-based immunotherapies and therapeutic vaccines derived from modified tumor-derived extracellular vesicles, with the goal of restoring anti-tumor immune responses in patients who do not respond well to checkpoint inhibitors. Its lead disclosed program, EV101, is being developed primarily for advanced and metastatic colorectal cancer, particularly micro-satellite stable disease, and has shown preclinical activity in animal models. EV Therapeutics positions its approach as both a monotherapy and a combination strategy with checkpoint blockade, leveraging a proprietary mTEV platform designed to enhance T-cell activation and tumor infiltration.